Women’s Health Today—April 15, 2026

This biweekly Women’s Health video recap highlights regulatory advances, clinical momentum, screening access efforts, biomarker insights, and evolving patient experience themes across gynecologic and breast cancers.

Dive deeper

In Today’s Newsletter

🧬 Dual-positive blood cells tied to breast cancer outcomes [1] [07 Apr 2026]

https://news.feinberg.northwestern.edu/2026/04/07/overlooked-cells-linked-to-poor-outcomes-in-breast-cancer/
Context: Northwestern investigators analyzed blood from 340 patients with advanced breast cancer and examined circulating tumor cells plus “dual-positive” cells.
Key point: DPcells were associated with worse overall survival, including in patients with fewer than five conventional CTCs; signal was strongest in triple-negative and HER2-positive disease [1].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🌍 Cervical cancer elimination remains an equity challenge [2] [Global • 01 Apr 2026]

https://healthpolicy-watch.news/eliminating-cervical-cancer-is-a-global-health-equity-challenge/
Context: Commentary cites WHO’s 90-70-90 targets for 2030 and highlights major disparities between lower-income and wealthier countries.
Key point: Authors argue cervical cancer is preventable and potentially eliminable, but financing, access, and women’s rights remain central barriers, especially in low- and middle-income countries [2].
Implication: May expand screening, initiation, and follow-up at scale.

🏠 At-home HPV screening clearance for Onclarity [3] [US • 08 Apr 2026]

https://www.prnewswire.com/news-releases/waters-announces-fda-clearance-of-the-most-comprehensive-at-home-cervical-cancer-screening-tool-the-onclarity-hpv-self-collection-kit-and-fda-approved-hpv-assay-302736967.html
Context: Waters said the FDA cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use.
Key point: The company positions the kit as a way to reduce screening barriers for unscreened and under-screened people, with prescription access and insurer coverage described in the release [3].
Implication: May expand screening, initiation, and follow-up at scale.

🎯 Corbus gets FDA alignment for CRB-701 in cervical cancer and HNSCC [4] [US • 07 Apr 2026]

https://ir.corbuspharma.com/news-events/press-releases/detail/463/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer
Context: Corbus said FDA broadly aligned on registrational study designs for CRB-701, a Nectin-4 ADC, in second-line HNSCC and cervical cancer.
Key point: Proposed studies use randomized comparisons, with ORR as the basis for potential accelerated approval and OS for potential full approval [4].
Implication: Signals pipeline investment and modality expansion.

💊 GSK posts early Mo-Rez response data in ovarian and endometrial cancers [5] [12 Apr 2026]

https://us.gsk.com/en-us/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynecological-cancers/
Context: In phase I BEHOLD-1, mocertatug rezetecan targeted B7-H4 in platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.
Key point: GSK reported confirmed ORR of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses evaluated; median duration of response was not yet reached [5].
Implication: May influence prescriber choice and payer reviews pending full data.

🗣️ Endometrial cancer survey highlights chemotherapy burden and unmet discussion needs [6] [US • 10 Apr 2026]

https://www.prnewswire.com/news-releases/new-survey-data-exploring-patient-experiences-with-endometrial-cancer-care-presented-at-2026-society-of-gynecologic-oncology-sgo-annual-meeting-on-womens-cancer-302738719.html
Context: Eisai reported survey findings from 119 U.S.-based patients with endometrial cancer who had received at least one line of chemotherapy.
Key point: Respondents described high chemotherapy burden, strong interest in alternatives, and a desire for more shared decision-making and discussion of treatment options beyond chemotherapy [6].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🚀 Fast Track for SIM0505 in platinum-resistant ovarian cancer [7] [09 Apr 2026]

https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-adc-for-platinum-resistant-ovarian-cancer
Context: FDA granted Fast Track designation to SIM0505, a CDH6-directed ADC being studied in a phase I program in advanced solid tumors, including platinum-resistant ovarian cancer.
Key point: The designation enables closer FDA engagement; the ongoing study includes dose escalation and dose optimization, with ovarian cancer among priority cohorts [7].
Implication: Signals pipeline investment and modality expansion.

🧪 Tumor-panel algorithm flags hereditary gynecologic cancer candidates [8] [South Korea • 03 Apr 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31178
Context: Seoul National University Bundang Hospital researchers developed an algorithm using tumor panel tiering plus variant allele frequency thresholds across 11 hereditary gynecologic cancer-related genes.
Key point: In 702 gynecologic cancer cases, the algorithm identified 19 patients for added hereditary testing; among four who underwent germline testing, all were confirmed hereditary cases [8].
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

Why It Matters

Cervical cancer remains a prevention-and-access story, with policy, screening tools, and health-system financing moving alongside therapeutics [2][3].
ADC momentum is accelerating across gynecologic cancers, from early efficacy readouts to Fast Track designations and registrational planning [4][5][7].
Patient experience is becoming more visible in endometrial cancer care, especially around chemotherapy burden and shared decision-making [6].
Biomarker and blood-based monitoring approaches continue to expand, including circulating-cell phenotyping in breast cancer and tumor-panel triage for hereditary risk [1][8].
Across these items, access and implementation matter as much as innovation, particularly for under-screened populations and lower-resource settings [2][3][6].

📚 View the full Women’s health archive on our research hub page.

🎯 Catch up on the Top Women’s Health news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

FAQ

What are DPcells in advanced breast cancer, and why do they matter?

DPcells are circulating cells that show both epithelial tumor markers and immune-cell markers. In the Northwestern study, their presence was linked to worse overall survival beyond standard CTC counts, especially in triple-negative and HER2-positive disease [1].

What changed for the Onclarity HPV Self-Collection Kit?

Waters said the FDA cleared the at-home self-collection kit and approved the paired BD Onclarity HPV Assay for home use. The company said this could broaden screening access for people who are unscreened or under-screened [3].

What did FDA alignment mean for CRB-701 in cervical cancer?

Corbus said FDA broadly aligned on randomized registrational studies in second-line cervical cancer and HNSCC. ORR would support potential accelerated approval, while OS would support potential full approval [4].

How strong are the early Mo-Rez data in ovarian and endometrial cancer?

GSK reported confirmed ORRs of 62% in platinum-resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer at the highest doses studied in phase I. These are early-stage data, with phase III trials planned in 2026 [5].

What does Fast Track add for SIM0505 in platinum-resistant ovarian cancer?

Fast Track can support more frequent FDA interaction and a potentially faster development path. SIM0505 remains investigational and is being studied in an ongoing phase I trial with ovarian cancer dose optimization planned [7].

How could the SNUBH algorithm affect hereditary gynecologic cancer testing?

The South Korean team used tumor-panel features to triage who may need germline testing, rather than testing everyone. That may help concentrate counseling and testing resources on higher-risk patients, pending further validation [8].

Entities / Keywords

Cervical cancer, HPV, HPV vaccination, HPV screening, WHO 90-70-90 targets, Onclarity HPV Self-Collection Kit, BD Onclarity HPV Assay, Waters Corporation, Becton Dickinson, CRB-701, Corbus Pharmaceuticals, Nectin-4 ADC, HNSCC, mocertatug rezetecan, Mo-Rez, GSK, B7-H4, BEHOLD-1, endometrial cancer, platinum-resistant ovarian cancer, PROC, SIM0505, NextCure, CDH6 ADC, Fast Track designation, circulating tumor cells, CTCs, DPcells, advanced breast cancer, hereditary gynecologic cancer, germline testing, variant allele frequency, Seoul National University Bundang Hospital